Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy

Antonio Curti, Alessandro Isidori, Elisa Ferri, Carolina Terragna, Paolo Neyroz, Claudia Cellini, Marina Ratta, Michele Baccarani, Roberto M. Lemoli

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Peripheral blood CD14+ monocytes from multiple myeloma (MM) patients can be induced to differentiate into fully functional, mature, CD83+ dendritic cells (DCs) which are highly efficient in priming autologous T lymphocytes in response to the patient-specific tumor idiotype (Id). We have recently scaled up our manufacturing protocol for application in a phase I-II clinical trial of anti-Id vaccination with DCs in MM patients. Elegible patients received a series of by-monthly immunizations consisting of three subcutaneous and two intravenous injections of Id-keyhole limpet hemocyanin (KLH)-pulsed DCs (5 × -, 10 × -, 50 × 106 cells and 10 × -, 50 × 106 cells, respectively). To generate DCs, monocytes were labeled with clinical grade anti-CD14 conjugates and positively selected by immunomagnetic separation. Cells were then cultured, according to Good Manufacturing Practice guidelines, in FCS-free medium in cell culture bags, and differentiated to DCs with GM-CSF plus IL-4 followed by TNF-α or, more recently, by a cocktail of IL-1β, IL-6, TNF-α and prostaglandin-E2. Before maturation, Mo-DCs were pulsed with the autologous Id as whole protein or Id (VDJ)-derived HLA class I restricted peptides. Ten MM patients, who had been treated with two courses of high-dose chemotherapy with peripheral blood stem cell support, entered into the clinical study. CD14+ monocytes were enriched from 16.1 ± 5.7% to 95.5 ± 3.2% (recovery 67.9 ± 15%, viability > 97%). After cell culture, phenotypic analysis showed that 89.6 ± 6.6% of the cells were mature DCs. We obtained 2.89 ± 1 × 108 DCs/leukapheresis which represented 24.5 ± 9% of the initial number of CD14+ cells. Notably, the cytokine cocktail induced a significantly higher percentage and yield (31 ± 10.9 of initial CD14+ cells of DCs than TNF-α alone, secretion of larger amounts of IL-12, potent stimulatory activity on allogeneic and autologous T cells. Storage in liquid nitrogen did not modify the phenotype or functional characteristics of pre-loaded DCs. The recovery of thawed, viable DCs, was 78 ± 10%. Thus, positive selection of CD14+ monocytes allows the generation of a uniform population of mature pre-loaded DCs which can be cryopreserved with no effects on phenotype and function and are suitable for clinical trials. Based on these results, a DCs-based phase II trial of anti-Id vaccination with VDJ-derived HLA class I-restricted peptides and KLH is underway for lymphoma patients.

Original languageEnglish
Pages (from-to)1419-1428
Number of pages10
JournalLeukemia and Lymphoma
Volume45
Issue number7
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Immunotherapy
Dendritic Cells
Monocytes
Neoplasms
Multiple Myeloma
Vaccination
Cell Culture Techniques
Immunomagnetic Separation
Leukapheresis
T-Lymphocytes
Phenotype
Phase II Clinical Trials
Peptides
Clinical Trials, Phase I
Interleukin-12
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-1
Practice Guidelines
Dinoprostone
Intravenous Injections

Keywords

  • CD14 cells
  • Cellular
  • Dendritic cells
  • Multiple myeloma
  • Tumor-associated antigens

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. / Curti, Antonio; Isidori, Alessandro; Ferri, Elisa; Terragna, Carolina; Neyroz, Paolo; Cellini, Claudia; Ratta, Marina; Baccarani, Michele; Lemoli, Roberto M.

In: Leukemia and Lymphoma, Vol. 45, No. 7, 07.2004, p. 1419-1428.

Research output: Contribution to journalArticle

Curti, A, Isidori, A, Ferri, E, Terragna, C, Neyroz, P, Cellini, C, Ratta, M, Baccarani, M & Lemoli, RM 2004, 'Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy', Leukemia and Lymphoma, vol. 45, no. 7, pp. 1419-1428. https://doi.org/10.1080/10428190310001653682
Curti, Antonio ; Isidori, Alessandro ; Ferri, Elisa ; Terragna, Carolina ; Neyroz, Paolo ; Cellini, Claudia ; Ratta, Marina ; Baccarani, Michele ; Lemoli, Roberto M. / Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 7. pp. 1419-1428.
@article{dbee44becc8949e09de61dd85b4d52d0,
title = "Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy",
abstract = "Peripheral blood CD14+ monocytes from multiple myeloma (MM) patients can be induced to differentiate into fully functional, mature, CD83+ dendritic cells (DCs) which are highly efficient in priming autologous T lymphocytes in response to the patient-specific tumor idiotype (Id). We have recently scaled up our manufacturing protocol for application in a phase I-II clinical trial of anti-Id vaccination with DCs in MM patients. Elegible patients received a series of by-monthly immunizations consisting of three subcutaneous and two intravenous injections of Id-keyhole limpet hemocyanin (KLH)-pulsed DCs (5 × -, 10 × -, 50 × 106 cells and 10 × -, 50 × 106 cells, respectively). To generate DCs, monocytes were labeled with clinical grade anti-CD14 conjugates and positively selected by immunomagnetic separation. Cells were then cultured, according to Good Manufacturing Practice guidelines, in FCS-free medium in cell culture bags, and differentiated to DCs with GM-CSF plus IL-4 followed by TNF-α or, more recently, by a cocktail of IL-1β, IL-6, TNF-α and prostaglandin-E2. Before maturation, Mo-DCs were pulsed with the autologous Id as whole protein or Id (VDJ)-derived HLA class I restricted peptides. Ten MM patients, who had been treated with two courses of high-dose chemotherapy with peripheral blood stem cell support, entered into the clinical study. CD14+ monocytes were enriched from 16.1 ± 5.7{\%} to 95.5 ± 3.2{\%} (recovery 67.9 ± 15{\%}, viability > 97{\%}). After cell culture, phenotypic analysis showed that 89.6 ± 6.6{\%} of the cells were mature DCs. We obtained 2.89 ± 1 × 108 DCs/leukapheresis which represented 24.5 ± 9{\%} of the initial number of CD14+ cells. Notably, the cytokine cocktail induced a significantly higher percentage and yield (31 ± 10.9 of initial CD14+ cells of DCs than TNF-α alone, secretion of larger amounts of IL-12, potent stimulatory activity on allogeneic and autologous T cells. Storage in liquid nitrogen did not modify the phenotype or functional characteristics of pre-loaded DCs. The recovery of thawed, viable DCs, was 78 ± 10{\%}. Thus, positive selection of CD14+ monocytes allows the generation of a uniform population of mature pre-loaded DCs which can be cryopreserved with no effects on phenotype and function and are suitable for clinical trials. Based on these results, a DCs-based phase II trial of anti-Id vaccination with VDJ-derived HLA class I-restricted peptides and KLH is underway for lymphoma patients.",
keywords = "CD14 cells, Cellular, Dendritic cells, Multiple myeloma, Tumor-associated antigens",
author = "Antonio Curti and Alessandro Isidori and Elisa Ferri and Carolina Terragna and Paolo Neyroz and Claudia Cellini and Marina Ratta and Michele Baccarani and Lemoli, {Roberto M.}",
year = "2004",
month = "7",
doi = "10.1080/10428190310001653682",
language = "English",
volume = "45",
pages = "1419--1428",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy

AU - Curti, Antonio

AU - Isidori, Alessandro

AU - Ferri, Elisa

AU - Terragna, Carolina

AU - Neyroz, Paolo

AU - Cellini, Claudia

AU - Ratta, Marina

AU - Baccarani, Michele

AU - Lemoli, Roberto M.

PY - 2004/7

Y1 - 2004/7

N2 - Peripheral blood CD14+ monocytes from multiple myeloma (MM) patients can be induced to differentiate into fully functional, mature, CD83+ dendritic cells (DCs) which are highly efficient in priming autologous T lymphocytes in response to the patient-specific tumor idiotype (Id). We have recently scaled up our manufacturing protocol for application in a phase I-II clinical trial of anti-Id vaccination with DCs in MM patients. Elegible patients received a series of by-monthly immunizations consisting of three subcutaneous and two intravenous injections of Id-keyhole limpet hemocyanin (KLH)-pulsed DCs (5 × -, 10 × -, 50 × 106 cells and 10 × -, 50 × 106 cells, respectively). To generate DCs, monocytes were labeled with clinical grade anti-CD14 conjugates and positively selected by immunomagnetic separation. Cells were then cultured, according to Good Manufacturing Practice guidelines, in FCS-free medium in cell culture bags, and differentiated to DCs with GM-CSF plus IL-4 followed by TNF-α or, more recently, by a cocktail of IL-1β, IL-6, TNF-α and prostaglandin-E2. Before maturation, Mo-DCs were pulsed with the autologous Id as whole protein or Id (VDJ)-derived HLA class I restricted peptides. Ten MM patients, who had been treated with two courses of high-dose chemotherapy with peripheral blood stem cell support, entered into the clinical study. CD14+ monocytes were enriched from 16.1 ± 5.7% to 95.5 ± 3.2% (recovery 67.9 ± 15%, viability > 97%). After cell culture, phenotypic analysis showed that 89.6 ± 6.6% of the cells were mature DCs. We obtained 2.89 ± 1 × 108 DCs/leukapheresis which represented 24.5 ± 9% of the initial number of CD14+ cells. Notably, the cytokine cocktail induced a significantly higher percentage and yield (31 ± 10.9 of initial CD14+ cells of DCs than TNF-α alone, secretion of larger amounts of IL-12, potent stimulatory activity on allogeneic and autologous T cells. Storage in liquid nitrogen did not modify the phenotype or functional characteristics of pre-loaded DCs. The recovery of thawed, viable DCs, was 78 ± 10%. Thus, positive selection of CD14+ monocytes allows the generation of a uniform population of mature pre-loaded DCs which can be cryopreserved with no effects on phenotype and function and are suitable for clinical trials. Based on these results, a DCs-based phase II trial of anti-Id vaccination with VDJ-derived HLA class I-restricted peptides and KLH is underway for lymphoma patients.

AB - Peripheral blood CD14+ monocytes from multiple myeloma (MM) patients can be induced to differentiate into fully functional, mature, CD83+ dendritic cells (DCs) which are highly efficient in priming autologous T lymphocytes in response to the patient-specific tumor idiotype (Id). We have recently scaled up our manufacturing protocol for application in a phase I-II clinical trial of anti-Id vaccination with DCs in MM patients. Elegible patients received a series of by-monthly immunizations consisting of three subcutaneous and two intravenous injections of Id-keyhole limpet hemocyanin (KLH)-pulsed DCs (5 × -, 10 × -, 50 × 106 cells and 10 × -, 50 × 106 cells, respectively). To generate DCs, monocytes were labeled with clinical grade anti-CD14 conjugates and positively selected by immunomagnetic separation. Cells were then cultured, according to Good Manufacturing Practice guidelines, in FCS-free medium in cell culture bags, and differentiated to DCs with GM-CSF plus IL-4 followed by TNF-α or, more recently, by a cocktail of IL-1β, IL-6, TNF-α and prostaglandin-E2. Before maturation, Mo-DCs were pulsed with the autologous Id as whole protein or Id (VDJ)-derived HLA class I restricted peptides. Ten MM patients, who had been treated with two courses of high-dose chemotherapy with peripheral blood stem cell support, entered into the clinical study. CD14+ monocytes were enriched from 16.1 ± 5.7% to 95.5 ± 3.2% (recovery 67.9 ± 15%, viability > 97%). After cell culture, phenotypic analysis showed that 89.6 ± 6.6% of the cells were mature DCs. We obtained 2.89 ± 1 × 108 DCs/leukapheresis which represented 24.5 ± 9% of the initial number of CD14+ cells. Notably, the cytokine cocktail induced a significantly higher percentage and yield (31 ± 10.9 of initial CD14+ cells of DCs than TNF-α alone, secretion of larger amounts of IL-12, potent stimulatory activity on allogeneic and autologous T cells. Storage in liquid nitrogen did not modify the phenotype or functional characteristics of pre-loaded DCs. The recovery of thawed, viable DCs, was 78 ± 10%. Thus, positive selection of CD14+ monocytes allows the generation of a uniform population of mature pre-loaded DCs which can be cryopreserved with no effects on phenotype and function and are suitable for clinical trials. Based on these results, a DCs-based phase II trial of anti-Id vaccination with VDJ-derived HLA class I-restricted peptides and KLH is underway for lymphoma patients.

KW - CD14 cells

KW - Cellular

KW - Dendritic cells

KW - Multiple myeloma

KW - Tumor-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=2542627346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542627346&partnerID=8YFLogxK

U2 - 10.1080/10428190310001653682

DO - 10.1080/10428190310001653682

M3 - Article

C2 - 15359643

AN - SCOPUS:2542627346

VL - 45

SP - 1419

EP - 1428

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -